Veracyte, Inc. (VCYT): Price and Financial Metrics


Veracyte, Inc. (VCYT): $20.11

0.21 (+1.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VCYT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VCYT POWR Grades


  • Growth is the dimension where VCYT ranks best; there it ranks ahead of 71.28% of US stocks.
  • The strongest trend for VCYT is in Sentiment, which has been heading down over the past 179 days.
  • VCYT ranks lowest in Momentum; there it ranks in the 5th percentile.

VCYT Stock Summary

  • For VCYT, its debt to operating expenses ratio is greater than that reported by merely 13.23% of US equities we're observing.
  • VCYT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 6.9% of US stocks.
  • As for revenue growth, note that VCYT's revenue has grown 86.85% over the past 12 months; that beats the revenue growth of 90.5% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Veracyte Inc are WISH, AWH, IGC, DGLY, and XGN.
  • VCYT's SEC filings can be seen here. And to visit Veracyte Inc's official web site, go to www.veracyte.com.

VCYT Valuation Summary

  • VCYT's price/earnings ratio is -51.5; this is 241.1% lower than that of the median Healthcare stock.
  • VCYT's price/sales ratio has moved down 3 over the prior 95 months.
  • Over the past 95 months, VCYT's price/sales ratio has gone down 3.

Below are key valuation metrics over time for VCYT.

Stock Date P/S P/B P/E EV/EBIT
VCYT 2021-08-31 20.6 3.3 -51.5 -43.9
VCYT 2021-08-30 20.9 3.4 -52.1 -44.5
VCYT 2021-08-27 20.4 3.3 -51.0 -43.5
VCYT 2021-08-26 19.0 3.1 -47.5 -40.2
VCYT 2021-08-25 19.0 3.1 -47.5 -40.2
VCYT 2021-08-24 18.0 2.9 -45.0 -37.8

VCYT Growth Metrics

    Its 2 year cash and equivalents growth rate is now at 453.9%.
  • Its 4 year net cashflow from operations growth rate is now at 71.82%.
  • Its 2 year net income to common stockholders growth rate is now at 29.93%.
VCYT's revenue has moved up $118,018,000 over the prior 34 months.

The table below shows VCYT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 219.514 -31.621 -75.563
2021-09-30 186.714 -37.806 -73.079
2021-06-30 157.465 -34.661 -63.074
2021-03-31 123.064 -44.971 -65.061
2020-12-31 117.483 -9.711 -34.909
2020-09-30 112.677 -10.182 -34.323

VCYT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VCYT has a Quality Grade of D, ranking ahead of 19.15% of graded US stocks.
  • VCYT's asset turnover comes in at 0.213 -- ranking 68th of 81 Healthcare stocks.
  • CHE, HCSG, and NTRA are the stocks whose asset turnover ratios are most correlated with VCYT.

The table below shows VCYT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.213 0.673 -1.427
2021-03-31 0.224 0.662 -1.543
2020-12-31 0.327 0.647 -0.827
2020-09-30 0.360 0.642 -0.795
2020-06-30 0.425 0.652 -0.693
2020-03-31 0.462 0.670 -0.490

VCYT Price Target

For more insight on analysts targets of VCYT, see our VCYT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $63.17 Average Broker Recommendation 1.5 (Moderate Buy)

VCYT Stock Price Chart Interactive Chart >

Price chart for VCYT

VCYT Price/Volume Stats

Current price $20.11 52-week high $54.13
Prev. close $19.90 52-week low $14.85
Day low $19.97 Volume 28,388
Day high $20.45 Avg. volume 949,477
50-day MA $18.73 Dividend yield N/A
200-day MA $32.03 Market Cap 1.44B

Veracyte, Inc. (VCYT) Company Bio


Veracyte Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company was founded in 2006 and is based in San Francisco, California.


VCYT Latest News Stream


Event/Time News Detail
Loading, please wait...

VCYT Latest Social Stream


Loading social stream, please wait...

View Full VCYT Social Stream

Latest VCYT News From Around the Web

Below are the latest news stories about Veracyte Inc that investors may wish to consider to help them evaluate VCYT as an investment opportunity.

Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT) and Atea Pharmaceuticals (AVIR)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Veracyte (VCYT – Research Report) and Atea Pharmaceuticals (AVIR – Research Report). Veracyte (VCYT) Leerink Partners analyst Puneet Souda maintained a Buy rating on Veracyte today and set a price target of $40.00. The company's shares closed last Monday at $27.80, close to its 52-week low of $22.00. According to TipRanks.

Howard Kim on TipRanks | March 1, 2022

Veracyte, Inc. 2021 Q4 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha | March 1, 2022

Veracyte to Participate in the Cowen 42nd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Participate in the Cowen 42nd Annual Health Care Conference

Business Wire | March 1, 2022

Veracyte GAAP EPS of -$0.15 beats by $0.04, revenue of $67.3M beats by $4.57M (NASDAQ:VCYT)

Veracyte press release (NASDAQ:VCYT): Q4 GAAP EPS of -$0.15 beats by $0.04.Revenue of $67.3M (+95.1% Y/Y) beats by $4.57M.

Seeking Alpha | February 28, 2022

Veracyte, Inc. (VCYT) CEO Marc Stapley on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 28, 2022

Read More 'VCYT' Stories Here

VCYT Price Returns

1-mo 15.97%
3-mo -30.70%
6-mo -51.19%
1-year -49.78%
3-year -30.63%
5-year 141.42%
YTD -51.19%
2021 -15.82%
2020 75.29%
2019 121.94%
2018 92.65%
2017 -15.63%

Continue Researching VCYT

Want to see what other sources are saying about Veracyte Inc's financials and stock price? Try the links below:

Veracyte Inc (VCYT) Stock Price | Nasdaq
Veracyte Inc (VCYT) Stock Quote, History and News - Yahoo Finance
Veracyte Inc (VCYT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.607 seconds.